TScan is advancing additional programs with the help of key collaborators, including academic institutions, pharmaceutical companies and other key partners.
Our proprietary platform technologies have broad potential for the discovery and development of new therapies for cancer, infectious diseases and autoimmune diseases. TScan is able to advance these programs through our in-house capabilities and also expand our reach through collaborations with academic intuitions, pharmaceutical companies and other key partners. For more information, please contact us at email@example.com.
Novartis Institutes for BioMedical Research, Inc.
In March 2020, we signed a strategic collaboration with Novartis to discover and develop novel T cell receptor-engineered T cell, or TCR-T, therapies for cancer.Read the press release »
QIAGEN Sciences, LLC
In November 2020, we signed a research license and option agreement with QIAGEN to develop COVID-19 T cell-based in vitro diagnostic products using SARS-CoV-2 specific peptides identified using the TargetScan discovery platform.Read the press release »
In October 2020, we entered into a research collaboration and license agreement with Poseida Therapeutics to explore development of TCR-T cell therapies for the treatment of COVID-19. The collaboration combines Poseida’s allogeneic T cell platform with TScan’s SARS-CoV-2-specific targets and TCRs identified using the TargetScan discovery platform.Read the press release »